NASDAQ:ANGN Angion Biomedica (ANGN) Stock Price, News & Analysis → Warning: this could blow your mind (From DTI) (Ad) Free ANGN Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.00▼$10.0052-Week Range N/AVolume224,800 shsAverage Volume86,718 shsMarket Capitalization$30.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Angion Biomedica alerts: Email Address Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Angion Biomedica Stock (NASDAQ:ANGN)Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.Read More Ad Behind the MarketsUrgent: Protect Your Investments from a Chinese InvasionAn alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.Click here to get my exclusive report NOW >>> ANGN Stock News HeadlinesJune 1, 2023 | finance.yahoo.comAngion Biomedia Corp. Announces 1-for-10 Reverse Stock SplitMay 2, 2023 | marketwatch.com8-K: Angion Biomedica Corp.March 28, 2024 | WealthPress (Ad)$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…April 27, 2023 | finance.yahoo.comCompanies Like Angion Biomedica (NASDAQ:ANGN) Could Be Quite RiskyApril 11, 2023 | markets.businessinsider.comSHAREHOLDER UPDATE: Halper Sadeh LLC Investigates CSII, ANGN, OSH, NUVAApril 6, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MPB, ANGN, TIGMarch 4, 2023 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BLI, DCT, ANGNFebruary 24, 2023 | stockhouse.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ANGN, OSH, IAAMarch 28, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. January 22, 2023 | benzinga.comMoore Kuehn Encourages NVCN, VLTA, CNCE, and ANGN Investors to Contact Law FirmJanuary 18, 2023 | benzinga.comSTOCKHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Angion Biomedica Corp. - ANGNJanuary 17, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Angion Biomedica Corp. MergerJanuary 17, 2023 | marketwatch.comAngion Biomedica Shares Tumble Premarket on Elicio Tie-Up >ANGNJanuary 17, 2023 | technews.tmcnet.comANGN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Angion Biomedica Corp. Is Fair to ShareholdersDecember 27, 2022 | finance.yahoo.comBullish insiders bet US$857k on Angion Biomedica Corp. (NASDAQ:ANGN)December 22, 2022 | finanznachrichten.deAngion Biomedica Corp.: Angion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsDecember 22, 2022 | finance.yahoo.comAngion Receives Nasdaq Notice Regarding Minimum Bid Price RequirementsNovember 29, 2022 | nasdaq.comNabriva (NBRV) Posts Positive Data From Cystic Fibrosis StudyNovember 29, 2022 | nasdaq.comAxsome (AXSM) Gains as Alzheimer's Agitation Study Meets GoalNovember 24, 2022 | msn.comReasons to Add Immunovant (IMVT) Stock to Your Portfolio NowNovember 17, 2022 | nasdaq.comImmunovant (IMVT) Rises More Than 150% in 3 Months: Here's HowNovember 10, 2022 | finance.yahoo.comJazz's (JAZZ) Q3 Earnings Beat Estimates, New Drugs Drive SalesNovember 4, 2022 | finance.yahoo.comKaruna Therapeutics (KRTX) Posts Wider-Than-Expected Q3 LossNovember 1, 2022 | finance.yahoo.comLilly (LLY) Beats on Q3 Earnings & Sales, Lowers '22 ViewOctober 13, 2022 | finance.yahoo.comIs Angion Biomedica (NASDAQ:ANGN) In A Good Position To Deliver On Growth Plans?September 24, 2022 | finance.yahoo.comAngion Biomedica Corp. (ANGN)September 12, 2022 | msn.comAngion Biomedica's Return On Capital Employed OverviewSee More Headlines Receive ANGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/12/2021Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:ANGN CUSIPN/A CIK1601485 Webwww.angion.com Phone415-655-4899FaxN/AEmployees3Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-38,810,000.00 Net MarginsN/A Pretax Margin-4,456.97% Return on Equity-47.53% Return on Assets-40.55% Debt Debt-to-Equity RatioN/A Current Ratio20.00 Quick Ratio20.00 Sales & Book Value Annual Sales$2.30 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.32 per share Price / BookN/AMiscellaneous Outstanding Shares30,110,000Free Float24,182,000Market Cap$30.11 million OptionableNot Optionable Beta0.60 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Jay R. Venkatesan M.B.A. (Age 51)M.D., Ph.D., Pres, CEO & Chairman Comp: $619.88kMs. Jennifer J. Rhodes J.D. (Age 53)Exec. VP, Chief Bus. Officer, Gen. Counsel, Chief Compliance Officer & Sec. Comp: $453.04kMr. Gregory S. Curhan (Age 61)Chief Financial Officer Mr. Daniel IazzettiVP of HRKey CompetitorsOrphazyme A/SNASDAQ:ORPHAileron TherapeuticsNASDAQ:ALRNFreeline TherapeuticsNASDAQ:FRLNUnity BiotechnologyNASDAQ:UBXLianBioNASDAQ:LIANView All Competitors ANGN Stock Analysis - Frequently Asked Questions How were Angion Biomedica's earnings last quarter? Angion Biomedica Corp. (NASDAQ:ANGN) issued its earnings results on Friday, November, 12th. The company reported ($5.30) EPS for the quarter, topping the consensus estimate of ($7.30) by $2.00. The business had revenue of $1.46 million for the quarter, compared to analyst estimates of $1.08 million. When did Angion Biomedica's stock split? Shares of Angion Biomedica reverse split on the morning of Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Angion Biomedica IPO? Angion Biomedica (ANGN) raised $75 million in an IPO on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel served as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers. This page (NASDAQ:ANGN) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceTop Project Outperforms BTC in 2023…Crypto 101 MediaThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Angion Biomedica Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.